Blueprint Medicines (Switzerland) GmbH
- Sector unverified
- Rank 280 / 334
Blueprint Medicines (Switzerland) GmbH is recorded by Swissmedic as the authorisation holder for 1 human medicine, which places it 280 of 334 authorisation holders. Its portfolio is mostly in the Synthetika category (100 % of its authorisations). We hold no research of our own on this company's sector or business model, so we assign it to none.
Sector unverified: the Swissmedic list carries no sector field and we have not researched this company.
Key facts
| Sector | Not available |
|---|---|
| City | Not available |
| Canton | Not available |
| Authorisation holder | Yes |
| Medicines | 1 |
| Founded | Not available |
| Employees | Not available |
| Parent group | Not available |
| Activity | Not available |
| Website | Not available |
Medicines authorised in Switzerland
Blueprint Medicines (Switzerland) GmbH is recorded by Swissmedic as the authorisation holder for 1 human medicine. The table shows 1 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
1 of 1 authorisation
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Ayvakyt 25 mg | 68294 | A | L01EX18 | 2023-07-06 |
Frequently asked questions
How many medicines does Blueprint Medicines (Switzerland) GmbH have authorised in Switzerland?
Blueprint Medicines (Switzerland) GmbH is recorded by Swissmedic as the authorisation holder for 1 human medicine (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Blueprint Medicines (Switzerland) GmbH based?
We have no confirmed Swiss address for Blueprint Medicines (Switzerland) GmbH. We add it as soon as the commercial register or the company confirms it.
Is Blueprint Medicines (Switzerland) GmbH a Swissmedic authorisation holder?
Yes. Blueprint Medicines (Switzerland) GmbH appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.